Supplement

You have full text access to this OnlineOpen article

Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis—United States, 2003 †‡§

  1. Donatus U. Ekwueme PhD1,¶,*,
  2. Harrell W. Chesson PhD2,
  3. Kevin B. Zhang PhD3,
  4. Appathurai Balamurugan MD, MPH4

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23761

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2936–2945, 15 November 2008

Additional Information

How to Cite

Ekwueme, D. U., Chesson, H. W., Zhang, K. B. and Balamurugan, A. (2008), Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis—United States, 2003 . Cancer, 113: 2936–2945. doi: 10.1002/cncr.23761

Author Information

  1. 1

    Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

  2. 2

    Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia

  3. 3

    Macro International, Calverton, Maryland

  4. 4

    Arkansas Central Cancer Registry/Epidemiology Branch, Arkansas Department of Health, Little Rock, Arkansas

  1. Fax: (770) 488-4639.

*Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, MS K-55, Atlanta, GA 30341;

  1. †

    The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

  2. ‡

    We sincerely thank Drs. Scott D. Grosse and Mercy Mvundura for providing us with the updated present value of future lifetime earnings data from 2000 to 2003. In addition, we are indebted to the anonymous reviewers for many helpful comments and suggestions.

  3. §

    This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Revised: 2 JUN 2008
  4. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (186K)

REFERENCES

  • 1
    Kessler RC,Greenberg PE,Mickelson KD,Meneades LM,Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med. 2001; 43: 218–225.
  • 2
    Chirikos TN,Russell-Jacobs A,Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract. 2002; 10: 248–255.
    Direct Link:
  • 3
    Walboomers JMM,Jacobs MV,Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical worldwide. J Pathol. 1999; 189: 12–19.
    Direct Link:
  • 4
    Franco EL,Rohan TE,Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst. 1999; 91: 506–511.
  • 5
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467–475.
  • 6
    Parkin DM,Bray F. Chapter 2: the burden of HPV-related cancers.Vaccine. 2006; 24( suppl 3): S11–S25.
  • 7
    Ries LAG,Harkins D,Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, Md: National Cancer Institute, SEER Program; 2006, Available at: http://seer.cancer.gov/csr/1975_2003/. Based on November 2005 SEER data submission, posted to the SEER website, 2006. Accessed December 10, 2007.
  • 8
    Horm JW,Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health. 1989; 79: 1490–1493.
  • 9
    Rainbolt T. Years of potential life lost: an evaluation of premature cancer deaths in Texas from 1981 through 1988. Tex Med. 1992; 88: 74–76.
  • 10
    Firman PC,Finney JW,Leibowitz JM. Years of potential life lost: evaluating premature cancer death in men. J Commun Health. 1989; 14: 101–106.
  • 11
    Albert VA,Koh HK,Geller AC,Miller DR,Prout MN,Lew RA. Years of potential life lost: another indicator of the impact of cutaneous malignant melanoma on society. J Am Acad Dermatol. 1990; 23(2 pt 1): 308–310.
  • 12
    Burnet NG,Jefferies SJ,Benson RJ,Hunt DP,Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden—and should be considered when allocating research funds. Br J Cancer. 2005; 92: 241–245.
  • 13
    Wong MD,Shapiro MF,Boscardin WJ,Ettner SL. Contribution of major diseases to disparities in mortality. N Engl J Med. 2002; 347: 1585–1592.
  • 14
    Brown ML,Lipscomb J,Snyder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001; 22: 91–13.
  • 15
    Brown ML,Hodgson TA,Rice DP. Chapter 13. Economic impact of cancer in the United States. In: SchottenfeldD,FrauminiJF, eds. Cancer Epidemiology and Prevention,2nd ed. New York, NY: Oxford University Press; 1996: 255–266.
  • 16
    Rice DP. Estimating the Cost of Illness. Health Economics Series, No. 6. Public Health Service Publication No. 947-6. Washington, DC: US Department of Health, Education, and Welfare; 1966.
  • 17
    Cooper BS,Rice DP. The economic cost of illness revisited. Soc Secur Bull. 1976; 39: 21–36.
  • 18
    Rice DP,Hodgson TA. Social and economic implications of cancer in the United States. Vital and Health Statistics, Series 3, No. 20. DHHS Publication No. PHS-81-1404. Public Health Service. Washington, DC: US Government Printing Office; 1981.
  • 19
    Hodgson TA,Rice DP. Chapter 12. Economic impact of cancer in the United States. In: SchottenfeldD,FraumeniJF, eds. Cancer Epidemiology and Prevention. Philadelphia, Pa: Saunders; 1982: 208–228.
  • 20
    Rice DO.Hodgson TA,Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985; 7: 61–80.
  • 21
    Rice DP,Hodgson TA,Capell F. The economic burden of cancer, 1985: United States and California. In: SchefflerR,AndrewsNC, eds. Cancer Care and Cost; DRGs and Beyond, Chapter 3. Ann Arbor, MI: Health Administration Press Perspectives; 1986: 39–59.
  • 22
    National Heart, Lung, and Blood Institute. Fact Book: Fiscal Year 2002. Bethesda, Md: National Institutes of Health; 2003. Available at: http://www.nhlbi.nih.gov/about/02factbk.pdf. Accessed December 10, 2007.
  • 23
    Max W,Rice DP,Sung HY,Michel M,Breuer W,Zhang X. The economic burden of gynecologic cancers in California, 1998. Gynecol Oncol. 2003; 88: 96–03.
  • 24
    Insinga RP. Annual productivity costs due to cervical cancer mortality in the United States. Womens Health Issues. 2006; 16: 236–242.
  • 25
    Rice DP,Kelman S,Miller LS,Dunmeyer S. The Economic Costs of Alcohol and Drug Abuse and Mental Illness. Rockville, Md: National Institute on Drug Abuse; 1990.
  • 26
    Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res. 1983; 4: 129–164.
  • 27
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Software [computer program]. Version 6.3.6. Bethesda, Md: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/seerstat/. Accessed December 10, 2007.
  • 28
    US Cancer Statistics Working Group. United States Cancer Statistics: 2003 Incidence and Mortality. Atlanta, Ga: Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2006. Available at: http://elib2.cdc.gov:2087/cancer/npcr/uscs. Accessed December 10, 2007.
  • 29
    National Center for Health Statistics. National Vital Statistics System. Atlanta, Ga: Centers for Disease Control and Prevention, National Center for Health Statistics; 2007. Available at: http://www.cdc.gov/nchs/nvss.htm. Accessed December 10, 2007.
  • 30
    Watson M,Saraiya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of human papillomavirus -associated cancers in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 2841–2854.
    Direct Link:
  • 31
    Fritz A,Percy C,Jack A, et al, eds. International Classification of Diseases for Oncology, 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
  • 32
    US Census Bureau. Current Population Survey, 2001-2004. Annual Social and Economic Supplements. Special Income Tabulation for the Year 2003. Washington, DC: Government Printing Office; 2004.
  • 33
    Grosse SD.Appendix I. Productivity loss tables. In: HaddixAC,TeutschSM,CorsoPS, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation,2nd ed. New York, NY: Oxford University Press; 2003: 245–257.
  • 34
    Arias E. United States Life Tables, 2003. National Statistics Reports, 54. Hyattsville Md: National Center for Health Statistics; 2006.
  • 35
    Fontaine KR,Redden DT,Wang C,Westfall AO,Allison DB. Years of life lost due to obesity. JAMA. 2003; 289: 187–193.
  • 36
    Rosenberg DC,Buescher PA. Years of Potential Life Lost by Sex, Race, and Ethnicity: North Carolina, 2000. A Special Report Series by the State Center for Health Statistics. No. 130, February 2002. Available at: http://www.schs.state.nc.us/SCHS/pdf/SCHS130.pdf. Accessed December 10, 2007.
  • 37
    Surveillance Epidemiology and End Results. 2000 US Standard Population Versus Standard Million. Bethesda, Md: National Cancer Institute, SEER Program; 2007; Available at: http://seer.cancer.gov/stdpopulations/single_age.html. Accessed December 10, 2007.
  • 38
    Max W,Rice DP,Sung H-Y,Michel M,Breuer W,Zhang X. The economic burden of prostate cancer, California, 1998. Cancer. 2002; 94: 2906–2913.
    Direct Link:
  • 39
    Corso PA,Haddix AC. Time effects. In: HaddixAC,TeutschSM,CorsoPS, eds. Prevention Effectiveness: A Guide to Decision Analysis and Economic Evaluation,2nd ed. New York, NY: Oxford University Press; 2003: 92–102.
  • 40
    Ries LAG,Eisner MP,Kosary CL, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, Md: National Cancer Institute; 2007. Available at:http://seer.cancer.gov/csr/1975_2004/. Accessed December 10, 2007.
  • 41
    Benard V,Thompson T,Johnson C, et al. Examining the association between socio-economic factors and potentially human papillomavirus-associated cancers. Cancer. 2008; 113( 10 suppl): 2910–2918.
    Direct Link:
  • 42
    Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics. 1992; 2: 1–4.
  • 43
    Hodgson TA,Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc. 1982; 60: 429–462.
  • 44
    National Cancer Institute (NIH). Cancer Trends Progress Report—2005 Update. Available at: http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2005&chid=25&coid=226&mid=. Accessed December 10, 2007.
  • 45
    Brown ML,Yabroff KR. Economic impact of cancer in the United States. In: SchottenfeldD,FaumeniJF, eds. Cancer Epidemiology and Prevention. New York, NY: Oxford University Press; 2006: 202–214.
  • 46
    Yabroff KR,Davis WW,Lamont EB, et al. Patient time costs associated with cancer care. J Natl Cancer Inst. 2007; 3:99: 14–23.
  • 47
    Hayman JA,Langa KM,Kabeto MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001; 19: 3219–3225.
  • 48
    Emanuel EJ,Fairclough DL,Slutsman J,Alpert H,Baldwin D,Emanuel LL. Assistance from family members, friends, paid care givers, and volunteers in the care of terminally ill patients. N Engl J Med. 1999; 341: 956–963.
  • 49
    Siegel K,Raveis VH,Houts P,Mor V. Caregiver burden and unmet patient needs. Cancer. 1991; 68: 1131–1140.
    Direct Link:
  • 50
    Covinsky KE,Goldman L,Cook EF, et al. The impact of serious illness on patients' families. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment. JAMA. 1994; 272: 1839–1844.
View Full Article (HTML) Get PDF (186K)